Pegylated recombinant factor IX (40 kDa)

pegylated recombinant factor IX · Novo Nordisk A/S

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Pegylated recombinant factor IX (40 kDa), covering 2017-01-20 to 2017-01-20. Get the full timeline:

Most recent: Clinical Trial Update: Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B [Phase 1]